Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Oct 16;20(1):149.
doi: 10.1186/s12954-023-00887-7.

Willingness to use a drug consumption room among people who use drugs in Lyon, France, a city with no open scene of drug use (the TRABOUL survey)

Mathieu Chappuy #  1   2   3   4 , Philippe Lack #  1 , Baptiste David  1 , Gilles Penavayre  5 , Damien Thabourey  5 , Maira Landulpho  5 , Anthony Plasse  6 , Christophe Icard  3 , François Bailly  1 , Faroudja Boutahra  7 , Pierre Pradat  8 , Marianne Maynard  8 , Marie Jauffret-Roustide  9   10   11 , Julia de Ternay  2   12 , Benjamin Rolland  13   14   15
Affiliations

Willingness to use a drug consumption room among people who use drugs in Lyon, France, a city with no open scene of drug use (the TRABOUL survey)

Mathieu Chappuy et al. Harm Reduct J. .

Abstract

Background: Drug consumption rooms (DCRs) have been developed in cities with open drug scenes, with the aim to reduce drug-related harm. In Lyon, France's second-largest city, there is no distinct drug use area, which raised doubts regarding the need for a DCR.

Methods: We conducted a face-to-face survey of 264 people who use drugs (PWUDs), recruited in harm reduction or addiction treatment centers, in the streets or in squats. We assess their willingness to use a DCR, and we collected sociodemographic and medical features. Bivariable comparisons and analyses adjusted for sociodemographic parameters explored the association between willing to use a DCR and other variables, thus providing crude (ORs) and adjusted odds ratios (aORs) and 95% confidence intervals (95% CI).

Results: In total, 193 (73.1%) PWUDs accepted to participate (mean age 38.5 ± 9.3 years; 80.3% men). Among them, 64.2% declared willing to use a DCR. Being treatment-seeker (aOR 0.20, 95% CI [0.08-0.51]; p < 0.001) and not living alone (aOR 0.29; 95% CI [0.10-0.86], p = 0.025) were negatively associated with willing to use a DCR. By contrast, receiving precarity social insurance (aOR 4.12; 95% CI [1.86-9.14], p < 0.001), being seropositive for hepatitis C (aOR 3.60; 95% CI [1.20-10.84], p = 0.022), being cannabis user (aOR 2.45; 95% CI [1.01-5.99], p = 0.049), and reporting previous problems with residents (aOR 5.99; 95% CI [2.16-16.58], p < 0.001) or with the police (aOR = 4.85; 95% CI [1.43-16.39], p = 0.011) were positively associated.

Conclusions: PWUDs, especially the most precarious ones, largely supported the opening of a DCR in Lyon, a city with no open drug scene.

Keywords: Drug consumption rooms; France; Harm reduction; Opioids; People who use drugs.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

References

    1. Potier C, Laprévote V, Dubois-Arber F, Cottencin O, Rolland B. Supervised injection services: what has been demonstrated? A systematic literature review. Drug Alcohol Depend. 2014;145:48–68. doi: 10.1016/j.drugalcdep.2014.10.012. - DOI - PubMed
    1. European Monitoring Center for Drugs and Drug Addiction. Drug consumption rooms: an overview of provision and evidence. 2018. https://www.emcdda.europa.eu/publications/pods/drug-consumption-rooms_en. Accessed Oct 1, 2023.
    1. Bourque S, Pijl EM, Mason E, Manning J, Motz T. Supervised inhalation is an important part of supervised consumption services. Can J Public Health. 2019;110(2):210–215. doi: 10.17269/s41997-019-00180-w. - DOI - PMC - PubMed
    1. Scherbaum N, Specka M, Bombeck J, Marrziniak B. Drug consumption facility as part of a primary health care centre for problem drug users - which clients are attracted? Int J Drug Policy. 2009;20(5):447–449. doi: 10.1016/j.drugpo.2009.01.001. - DOI - PubMed
    1. Wilson DP, Donald B, Shattock AJ, Wilson D, Fraser-Hurt N. The cost-effectiveness of harm reduction. Int J Drug Policy. 2015;26(Suppl 1):S5–11. doi: 10.1016/j.drugpo.2014.11.007. - DOI - PubMed